SEC Form 4 · accession 0001179110-17-012138
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J Foley
Director
Period of report
Sep 5, 2017
Accepted (ET)
Sep 7, 2017 · 8:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 5, 2017 | A | 6,000 | $0.00 | A | 6,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $24.55 | Sep 5, 2017 | A | 12,000 | A | — | Sep 4, 2027 | Common Stock | 12,000 | 12,000 | D |
Explanation of responses
- F1Represents a restricted stock award (the "RSA"). The shares underlying the RSA shall vest on September 5, 2018, the one year anniversary of the grant date, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan") through such vesting date.
- F2The shares subject to the stock option shall vest on September 5, 2018, the one year anniversary of the grant date, subject to Mr. Foley's Continuous Service (as defined in the Plan) through such vesting date.